Glioma angiogenesis: Towards novel RNA therapeutics

Cell Adhesion and Migration

Volumn 3, Issue 2, 2009, Pages 230-235

  Würdinger, Thomas ^a,b,c   Tannous, Bakhos A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Amsterdam Gastroenterology Metabolism   (Netherlands)

Author keywords

Angiogenesis; Anti angiogenesis therapy; Blood vessels; Endothelial cells; Glioma; miRNA; siRNA

Indexed keywords

AGN 211745; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEVASIRANIB; CILENGITIDE; ENDOSTATIN; IRINOTECAN; MICRORNA; MIR 126; MIR 221; MIR 222; MIR 296; SHORT HAIRPIN RNA; SIRNA 027; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; ARTHRITIS; GLIOBLASTOMA; GLIOMA; HUMAN; NONHUMAN; RETINA MACULA DEGENERATION; REVIEW; RNA INTERFERENCE; SUBRETINAL NEOVASCULARIZATION; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

EID: 66749140894     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.3.2.7910     Document Type: Review

References (78)

1. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005; 15:297-310. (Pubitemid 41677429)
2. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48:347-356
3. Folkerth RD. Descriptive analysis and quantification of angiogenesis in human brain tumors. J Neurooncol 2000; 50:165-172 (Pubitemid 32166298)
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-739 (Pubitemid 37328908)
5. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, et al. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003; 116:1013-1022 (Pubitemid 36395612)
6. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006; 118:2182-2189
7. Miebach S, Grau S, Hummel V, Rieckmann P, Tonn JC, Goldbrunner RH. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol 2006; 76:39-48. (Pubitemid 43115757)
8. Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 2008; 10:23.
9. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004; 70:217-228 (Pubitemid 39545733)
10. Bansal K, Liang ML, Rutka JT. Molecular biology of human gliomas. Technol Cancer Res Treat 2006; 5:185-194 (Pubitemid 43946252)
11. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol 2008; 5:476-486
12. Chakravarti A, Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 2008; 139:173-189
13. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62. (Pubitemid 40093472)
14. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 5:20-27 (Pubitemid 30225453)
15. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 2006; 6:1087-1104 (Pubitemid 44203386)
16. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008; 6:515-522
17. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6:273-286
18. Folkman J. Endogenous angiogenesis inhibitors. Apmis 2004; 112:496-507. (Pubitemid 39626056)
19. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24:1253-1265 (Pubitemid 46622028)
20. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007; 114:443-458 (Pubitemid 47521501)
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
22. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginineglycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008; 17:1225-1235
23. Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas. Front Biosci 1999; 4:188-199
24. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19:29-34. (Pubitemid 32054367)
25. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun Y, et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 2004; 10:1255-1262 (Pubitemid 38365215)
26. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24:3555-3561 (Pubitemid 46630526)
27. Twombly R. First clinical trials of endostatin yield lukewarm results. J Natl Cancer Inst 2002; 94:1520-1521 (Pubitemid 35277272)
28. Bello L, Lucini V, Giussani C, Carrabba G, Pluderi M, Scaglione F, et al. IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery 2003; 52:177-185 (Pubitemid 36098668)
29. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 2000; 46:135-144
30. Ren H, Yang BF, Rainov NG. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev Recent Clin Trials 2007; 2:87-101. (Pubitemid 46773876)
31. Desjardins A, Reardon DA, Herndon JE, 2nd, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clin Cancer Res 2008; 14:7068-7073
32. Boutros M, Ahringer J. The art and design of genetic screens: RNA interference. Nat Rev Genet 2008; 9:554-566
33. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431:371-378 (Pubitemid 39265678)
34. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008; 68:1029-1036
35. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008; 19:125-132
36. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 2004; 1:165-176
37. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007; 13:4051-4060
38. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M, et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 2008; 27:4830-4840
39. Niola F, Evangelisti C, Campagnolo L, Massalini S, Bue MC, Mangiola A, et al. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 2006; 5:174-179 (Pubitemid 43327537)
40. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120:338-346 (Pubitemid 34250056)
41. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9:210-216 (Pubitemid 38097589)
42. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431 (Pubitemid 44511557)
43. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13:225-234 (Pubitemid 43148645)
44. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452:591-597
45. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 2001; 413:732-738 (Pubitemid 33009951)
46. Rossi J, Zamore P, Kay MA. Wandering eye for RNAi. Nat Med 2008; 14:611.
47. Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 2008; 58:2356-2367
48. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21:635-637 (Pubitemid 36638089)
49. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003; 17:438-442
50. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006; 21:533-542 (Pubitemid 43228008)
51. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003; 100:9779-9784 (Pubitemid 37087018)
52. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769-773 (Pubitemid 40292988)
53. Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J 2007; 7:297-304. (Pubitemid 47471308)
54. Chen C, Chai H, Wang X, Jiang J, Jamaluddin MS, Liao D, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112:3205-3216
55. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38:1060-1065 (Pubitemid 44325933)
56. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15:272-284
57. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101:59-68. (Pubitemid 47094624)
58. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008.
59. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108:3068-3071 (Pubitemid 44776946)
60. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007; 100:1164-1173 (Pubitemid 46684129)
61. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15:261-271
62. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, et al. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997; 272:11994-12000 (Pubitemid 27202775)
63. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005; 33:1290-1297 (Pubitemid 41439922)
64. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006; 34:2294-2304 (Pubitemid 43985667)
65. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004; 279:52361-52365 (Pubitemid 39656612)
66. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. PLoS Biol 2004; 2:98. (Pubitemid 39234504)
67. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the downregulation of putative targets during differentiation. J Biol Chem 2005; 280:16635-16641 (Pubitemid 41389120)
68. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431:343-349 (Pubitemid 39265674)
69. Bhat B, Esau C, Davis S, Propp S, Kinberger G, Gaus H, et al. 2′-O-Methoxyethyl/2′-Fluoro Modified Oligonucleotides Result in More Potent Inhibition of micro RNA-122 in Vivo: A Target implicatedin HCV Replication. Nucleic Acids Symp Ser (Oxf) 2008; 69.
70. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-899
71. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to upregulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36:1153-1162
72. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372:137-141
73. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004; 43:13233-13241
74. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15amiR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14:1271-1277
75. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-689
76. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008; 14:382-393
77. Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 Expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2008.
78. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126:1203-1217 (Pubitemid 44380294)